Relmada Therapeutics(RLMD) - 2024 Q4 - Annual Results

Financial Performance - The net loss for Q4 2024 was $18.6 million, or$ 0.62 per share, compared to a net loss of $25.1 million, or$ 0.84 per share, in Q4 2023[7] - The net loss for the full year 2024 was $80 million, or$ 2.65 per share, compared to a net loss of $98.8 million, or$ 3.28 per share, in 2023[13] - Net loss for 2024 was $79,979,354, compared to a net loss of$ 98,791,746 in 2023, indicating an improvement of about 19%[33] Cash and Assets - The company reported a cash balance of $44.8 million as of December 31, 2024[1] - Cash and cash equivalents decreased to$ 3,857,026 as of December 31, 2024, down from $4,091,568 as of December 31, 2023[30] - Total current assets fell to$ 45,795,843 in 2024 from $97,508,917 in 2023, a decline of approximately 53%[30] Expenses - Research and development expenses for Q4 2024 totaled$ 11.0 million, a decrease of 25.2% from $14.7 million in Q4 2023[7] - General and administrative expenses for Q4 2024 were$ 8.1 million, down approximately 33.1% from $12.1 million in Q4 2023[7] - For the full year 2024, research and development expenses totaled$ 46.2 million, down from $54.8 million in 2023, a decrease of 15.7%[13] - Total operating expenses decreased to$ 83,891,036 in 2024 from $103,702,293 in 2023, representing a reduction of approximately 19%[33] - Research and development expenses decreased to$ 46,175,512 in 2024 from $54,807,348 in 2023, a reduction of approximately 16%[33] - General and administrative expenses decreased to$ 37,715,524 in 2024 from $48,894,945 in 2023, a decline of about 23%[33] Equity and Liabilities - Additional paid-in capital increased to$ 676,373,822 in 2024 from $646,229,824 in 2023, reflecting an increase of about 5%[30] - Total liabilities decreased to$ 10,295,857 in 2024 from $12,194,800 in 2023, a reduction of approximately 16%[30] - Stockholders' equity decreased to$ 35,521,961 in 2024 from $85,357,242 in 2023, a decline of about 58%[30] Development Programs - The company is advancing NDV-01, a Phase 2 program for high-grade non-muscle invasive bladder cancer, with topline data expected at AUA 2025[4] - Sepranolone, a Phase 2b-ready neurosteroid for Tourette syndrome, is also being developed with plans for evaluation in other compulsion-related disorders[4] - The company aims to initiate a registration-track study for NDV-01 in late Q4 2025 to early 2026[7] - The U.S. NMIBC market is estimated to be a multi-billion opportunity, driven by the increasing incidence of bladder cancer and demand for effective therapies[15] Share Information - The weighted average number of common shares outstanding increased to 30,163,751 in 2024 from 30,099,203 in 2023[33]